UNIPHARMA INSIGHTS
Search insights
Signal flow
Servier has closed its Day One acquisition, taking control of U.S.-marketed OJEMDA and adding a rare cancer pipeline while ex-U.S. rights remain licensed to Ipsen.
Reference pages
7 pages visible
Aspirin is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageChlorphenamine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageMexiletine is tracked by UniPharma because changes in supply, manufacturing, regulation, or demand can affect sourcing and market decisions for pharma teams operating across Europe and the UK.
Open pageDrug shortage supplier is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageEarly Access Medicine is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageUnlicensed Medicines is tracked by UniPharma when it has a clear effect on sourcing, regulation, access, or commercial execution for pharma teams.
Open pageOncology is monitored by UniPharma because shifts in demand, reimbursement, regulation, competition, or supply priorities can reshape procurement and launch planning.
Open pageContact us
Bring us the access challenge, the shortage pressure or the regulated logistics brief. We will turn it into a clean operating plan.
